FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL
			OMB Number:          3235-0287
			Expires:           January 31, 2005
[_]	Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Respones)		Estimated average burden hours per response.                               0.5

1. Name and Address of Reporting Person* O'Donnell John P.	2. Issuer Name and Ticker or Trading Symbol Mylan Laboratories Inc. (MYL)		6. Relationship of Reporting Person(s) to Issuer (Check all applicable) [_]    Director                                   [_]   10% Owner [X]    Officer (give title below)             [_]   Other (specify below)                                      Chief Scientific Officer
(Last)             (First)            (Middle) 24 Heather Drive	3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	4. Statement for Month/Day/Year February 5, 2003
(Street) Morgantown, WV 26505		5. If Amendment, Date of Original (Month/Day/Year)	7. Individual or Joint/Group Filing (Check Applicable Line) [X]  Form filed by One Reporting Person [_] Form filed by More than One Reporting Person
(City)             (State)             (Zip)	Table I — Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans- action Date (mm/dd/yy)	2A. Deemed Execution Date, if any (mm/dd/yy)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction (Instr. 3 and 4)	6. Owner- ship Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Mylan Laboratories Inc. Common Stock	02/05/03		S		20,000	D	$26.24	4,450	D
Mylan Laboratories Inc. Common Stock	02/05/03		I		5,018	D	$25.94	3,075	I	Shares held in 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.         Mylan Laboratories Inc. Incurred a 3 for 2 stock split on January 27, 2003. Shares reported are on a post-split basis. * If the form is filed by more than one reporting person, see Instructions 4(b)(v).
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently vaild OMB control Number.	(Over) SEC 1474 (9-02)

FORM 4 (continued) Table II —Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1.Title of Derivative Security (Instr.3)

2.  Conversion or Exercise Price of Derivative Security

3.  Transaction Date (Month/ Day/ Year)

3A. Deemed Execution Date if any (Month/ Day/ Year)

4. Transaction Code  Instr. 8)

5. Number of Derivative Securities  Acquired (A) or Disposed of  (D)  (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9.Number of Deriv- ative Secur- ities Bene- ficially Owned Follow- ing Reported Trans- action(s) (Instr. 4)

10. Owner- ship Form of Deriv- ative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Benefi- cial Owner- ship (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Explanation of Responses:      Mylan Laboratories Inc. Incurred a 3 for 2 stock split on January 27, 2003. Shares reported are on a post-split basis.

**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	/s/  John P. O'Donnell **Signature of Reporting Person	2/7/2003   Date
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number. Page 2